TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

/PRNewswire/ -- Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of...

Related Keywords

San Antonio ,Texas ,United States ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Vilaseca ,American ,Prnewswire Johnson ,Sabine Brookman ,Rodriguez Faba ,Ania Diantonio ,Indianj Urol ,American Cancer Society ,American Urological Association ,Janssen Pharmaceuticals ,Johnson ,Janssen Research Development ,Drug Administration ,Astex Pharmaceuticals ,Late Development Oncology ,European Association Of Urology ,Bladder Cancer Advocacy Network ,European Society For Medical Oncology ,Exchange Commission ,None Of Janssen Research Development ,Janssen Biotech Inc ,Oral Presentation Session ,Urological Association ,Annual Meeting ,Bacillus Calmette Gu ,European Society ,Medical Oncology ,European Association ,Antoni Vilaseca ,Sabine Brookman May ,Vice President ,Johnson Innovative ,Breakthrough Therapy Designation ,European Medicines Agency ,Soft Tissue Mineralization ,Embryo Fetal Toxicity ,High Risk Non ,Muscle Invasive Bladder Cancer ,Innovative Medicine ,Janssen Research ,Janssen Biotech ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Urology Young Academic Urologists ,Urol Assoc ,Bladder Cancer Advocacy ,Accessed April ,Johnson Amp ,